Shares of Moderna dropped 4.9% to $93.15 on Tuesday, on what attested to be an all-around negative trading session for the stock market, with the Nasdaq Stock Market falling by 0.21% to $11899.3.
Moderna closed at $97.95, below its 52-week high of $103.2.
Moderna’s sales growth is 1074.4% for the ongoing quarter and 2299% for the next. The company’s growth estimates for the present quarter is a negative 75.7% and a positive 142.9% for next quarter.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s stock is valued at $93.15, lower than its 52 Week High of $103.2 but way above its 52 Week Low of $17.68.
Moderna’s worth is way above its 50 day moving average of $73.62 but way higher than its 200 day moving average of $68.29.